A substudy examining participants with metabolic-associated steatotic liver disease produced results that no pharmacological intervention had previously achieved
If you take a reduced dose, you run the risk of the drug disappearing from your system faster than intended, explains Dr
[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Each of the three receptor pathways it activates contributes a different piece to the overall weight loss effect
This helps the provider determine your target dose
The NHS is currently running trials to see how well retatrutide works for people living with excess weight or obesity